TScan Therapeutics, Inc. (TCRX)
0.2377
+0.03
(+12.87%)
USD |
NASDAQ |
Oct 15, 16:00
0.2377
0.00 (0.00%)
After-Hours: 20:00
TScan Therapeutics Max Drawdown (5Y) : 96.78% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 96.78% |
| August 31, 2026 | 94.63% |
| July 31, 2026 | 94.50% |
| June 30, 2026 | 93.77% |
| May 31, 2026 | 93.36% |
| April 30, 2026 | 93.36% |
| March 31, 2026 | 93.36% |
| Date | Value |
|---|---|
| February 28, 2026 | 93.36% |
| January 31, 2026 | 93.36% |
| December 31, 2025 | 93.36% |
| November 30, 2025 | 92.86% |
| October 31, 2025 | 91.84% |
| September 30, 2025 | 91.84% |
| August 31, 2025 | 91.84% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| Agenus, Inc. | 98.84% |
| Amgen, Inc. | 24.86% |
| Anika Therapeutics, Inc. | 83.15% |
| BioCryst Pharmaceuticals, Inc. | 79.10% |
| Imunon, Inc. | 99.49% |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -63.36 |
| Beta (5Y) | 1.148 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 86.11% |
| Historical Sharpe Ratio (5Y) | -0.6024 |
| Historical Sortino (5Y) | -1.074 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 39.02% |